tetano
Editor, Senior Moderator
ASAIO J. 2020 Apr 30. doi: 10.1097/MAT.0000000000001180. [Epub ahead of print]
Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIO-A "Living Working Document".
Rajagopal K[SUP]1,[/SUP][SUP]2[/SUP], Keller SP[SUP]3[/SUP], Akkanti B[SUP]4[/SUP], Bime C[SUP]5[/SUP], Loyalka P[SUP]2[/SUP], Cheema FH[SUP]1,[/SUP][SUP]2,[/SUP][SUP]6[/SUP], Zwischenberger JB[SUP]7[/SUP], El Banayosy A[SUP]8[/SUP], Pappalardo F[SUP]9[/SUP], Slaughter MS[SUP]10[/SUP], Slepian MJ[SUP]10[/SUP].
Author information
Abstract
The severe acute respiratory syndrome (SARS)-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 (COVID)-19 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of COVID-19; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from ASAIO. Of note, this is a "living document," which will be updated periodically, as additional information and understanding emerges.
PMID:32358232DOI:10.1097/MAT.0000000000001180
Advanced Pulmonary and Cardiac Support of COVID-19 Patients: Emerging Recommendations From ASAIO-A "Living Working Document".
Rajagopal K[SUP]1,[/SUP][SUP]2[/SUP], Keller SP[SUP]3[/SUP], Akkanti B[SUP]4[/SUP], Bime C[SUP]5[/SUP], Loyalka P[SUP]2[/SUP], Cheema FH[SUP]1,[/SUP][SUP]2,[/SUP][SUP]6[/SUP], Zwischenberger JB[SUP]7[/SUP], El Banayosy A[SUP]8[/SUP], Pappalardo F[SUP]9[/SUP], Slaughter MS[SUP]10[/SUP], Slepian MJ[SUP]10[/SUP].
Author information
Abstract
The severe acute respiratory syndrome (SARS)-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 (COVID)-19 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of COVID-19; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from ASAIO. Of note, this is a "living document," which will be updated periodically, as additional information and understanding emerges.
PMID:32358232DOI:10.1097/MAT.0000000000001180